Previous 10 | Next 10 |
It's a familiar story. A small biotech gets really good news about a promising drug. A big drugmaker with deep pockets is looking for a way to fuel growth. The big drugmaker thinks the small biotech's drug is a good fit with its own lineup and acquires the small biotech. And investors who owned ...
Are there other aspects of the business, somewhat peculiar to the industry involved, which will give the investor important clues as to how outstanding the company may be in relation to its competition? - Phillip Fisher If you've been following my coverage of Amarin Corporation ( AMRN ...
Gainers: NSCO +37.0% . AVID +11.5% . CRC +4.9% . PPDF +4.1% . ENDP +2.3% . More news on: Nesco Holdings, Inc., Avid Technology, Inc., California Resources Corporation, Stocks on the move, Read more ...
Oppenheimer initiates Amarin (NASDAQ: AMRN ) with an Underperform rating and $7 price target, suggesting a whopping 70% downside from this afternoon's close. More news on: Amarin Corporation plc, Acasti Pharma Inc., Healthcare stocks news, Stocks on the move, Quick stock ideas,...
The EVAPORATE study is being conducted on Amarin's (AMRN) Vascepa by a team of non-Amarin affiliated researchers led by Dr Matthew Budoff, MD, professor of medicine at David Geffen School of Medicine at UCLA. The "purpose of this study is to determine whether the addition of IPE 4g/d will resu...
November 19, 2019 Palm Beach, FL –November 19, 2019 – A lot of cancer research is dealing with shrinking brain tumors and opening the door for targeted cancer therapies to work without damaging the surrounding tissue. The success rate for cancer therapies has been limite...
REDUCE-IT USA results, in prespecified subgroup analyses, showed cardiovascular risk reductions across all endpoints, including 30% relative risk reduction in all-cause mortality New analysis determined icosapent ethyl ( Vascepa ® ) is highly cost-effective in...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that John F. Thero, president and chief executive officer of Amarin, has been named EY...
Amarin ( AMRN -5.5% ) slips on more than double normal volume as investors take some money off the table after last week's 37% rally related to the positive Ad Com vote on a CV benefit claim for Vascepa (icosapent ethyl). More news on: Amarin Corporation plc, Healthcare stock...
Acasti Pharma (NASDAQ: ACST ) resume with Buy rating and $8 (292% upside) price target at B. Riley FBR. Shares up 5% premarket. More news on: Acasti Pharma Inc., Champions Oncology, Inc., DexCom, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...